Tagged with access,

UK With over 30 years of experience in the life sciences industry, Angela McFarlane explains why the UK will not be removed from its position in the top 3 for new chemical entity launches, after USA and Germany, despite the uncertainty created by Brexit. Furthermore, she highlights the fact that the…

Turkey Elif Aral, country manager of Pfizer Turkey, stresses that Turkey will continue to be perceived as essential and important, where healthcare is a top priority with its young but aging population. In addition, as the newly appointed Chairman of the Board of Directors of the Association of Research-Based Pharmaceutical Companies…

Turkey Mark Dekker, general manager of Astellas in Turkey, describes the ever-increasing commitment of the company to Turkey and the recent doubling of Astellas’ portfolio in the country, while pinpointing the next steps ahead to further improve access to innovation in Turkey and ensure the country continues to be seen as…

Hong Kong Merck Hong Kong’s Hee-sun Lee gives her first impressions of the Hong Kong market, her main priorities, upcoming product launches and tapping into the territory’s R&D ecosystem. Hee-sun, having joined Merck Pharmaceutical Hong Kong in February 2018 from the South Korean affiliate, what are your first impressions of the market…

UK Richard Erwin, general manager of Roche Products Ltd in the UK, speaks out about the challenges facing the company, from market access to uptake of innovation, to collaborating with diverse stakeholder groups, improving outcomes for UK patients.   We do see a will and an intent from stakeholders, from government…

UK Having just announced a major investment into a new UK Discovery Centre in London that is set to open in 2020, MSD is committed to leverage on the UK’s potential in driving forward early stage discovery. Louise Houson, Managing Director for the UK and Ireland explains the reasons for that…

UK Britain, home of the discovery of the world’s first ever vaccine, has long been championing a pharma sub-segment forecast to reach a global market value of USD 49.27 billion by 2022. However, despite possessing the innovators, the infrastructure and the coverage, the UK’s thriving vaccine industry risks being blown off…

Portugal Hailing from the Dominican Republic, Silvia Guichardo brings a fresh perspective as well as both US and Iberian experience to GSK Portugal. Six months into her role as general manager, Guichardo highlights GSK’s historic commitment to Portuguese patients, new therapeutic areas for 2019, and the unsung importance of leading a…

Spain Concha Almarza, general manager at IQVIA Spain, discusses the changes that the Spanish pharmaceutical market has witnessed over the last few years, highlighting the stringent cost-containment measures aimed at improving patient access to complex innovative drugs, the stabilization of generics penetration urging producers to expand their offering to other segments,…

Portugal Cristina Campos is well known on the Portuguese pharmaceutical circuit, directing the affiliate of market leader, Novartis, and holding a position as vice-president at APIFARMA, the Portuguese Pharmaceutical Association. In her second meeting with PharmaBoardroom, Campos discusses the Portuguese ‘talent machine’, an exciting new portfolio with incredibly strong launches on…

UK Only 14 months in position, UK country president at Novartis, Haseeb Ahmad, shares insights into the company’s new strategy. He further analyses how Brexit can be a catalysing force for the UK to lead in life sciences and explains why the country has potential as a test bed for medicine…

India Luca Visini, the recently appointed managing director of Eli Lilly & Company for India, shares with us his first perspective of the Indian ecosystem He also provides insights into some of his key objectives in India, which include consolidating the reputation of Eli Lilly as a key stakeholder in the…